Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

301.37 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
55 56 Next >
Unpacking the Latest Options Trading Trends in Amgen
 
Via Benzinga
Peering Into Amgen's Recent Short Interest
 
Via Benzinga
3 High-Yield Dividend Stocks to Buy in 2025
Via The Motley Fool
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. 
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Analyst Expectations For Amgen's Future
 
Via Benzinga
Looking At Amgen's Recent Unusual Options Activity
 
Via Benzinga
UK Greenlights Amgen's Drug For Aggressive Lung Cancer In Pretreated Patients
Amgen's Imdylltra gets MHRA nod for ES-SCLC after two prior therapies, offering new hope for aggressive cancer with limited treatment options. 
Via Benzinga
Prediction: These 3 Healthcare Stocks Will Soar in 2025
Via The Motley Fool
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Stocks
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
 
Via Benzinga
Dissecting Our Discipline
All portfolio managers practice a stock-picking discipline in which they make choices. 
Via Talk Markets
Topics Stocks / Equities
Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025
In the Dow Jones Industrial Average, 28 of the 30 components pay dividends. With changes to the components in 2024, dividend yield is smaller overall. 
Via Benzinga
Topics Stocks
Spotlight on Amgen: Analyzing the Surge in Options Activity
 
Via Benzinga
3 Worst Performing Dow Jones Stocks In 2024
The Dow Jones Industrial Average will finish 2024 with a positive return. The index has climbed about 24% this year. 
Via Talk Markets
Topics Stocks Stocks / Equities
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
The Schwab US Dividend Equity ETF has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be plaguing the fund: 
Via Benzinga
Topics ETFs
2 Excellent Dividend Stocks to Buy on the Dip
Via The Motley Fool
What's Going On With Amgen Stock On Friday?
Novo Nordisk's CagriSema shows 22.7% weight loss in Phase 3 trials, while tolerability concerns grow. MariTide offers competitive weight loss with less frequent dosing. 
Via Benzinga
Unpacking the Latest Options Trading Trends in Amgen
 
Via Benzinga
Demystifying Amgen: Insights From 13 Analyst Reviews
 
Via Benzinga
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future. 
Via Investor's Business Daily
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.
Eli Lilly and Viking Therapeutics jumped on Novo's setback. 
Via Investor's Business Daily
10 Biggest Losers of The Dow Jones Index's 10-Day Losing Streak
Investors shrugged off the meltdown on Thursday. A few Dow laggards rebounded. 
Via Investor's Business Daily
Topics Stocks
Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease
The company's drug led to an improvement in diplopia, or double vision, an area where Amgen's Tepezza hasn't worked. 
Via Investor's Business Daily
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
The weight-loss drugs space continues to heat up. Here's the latest news from the segment. 
Via Investor's Business Daily
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends. 
Via Benzinga
These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over
Via The Motley Fool
Topics Stocks
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
2 No-Brainer Dividend Stocks With Yields Over 3% to Buy in 2025 and Hold for a Decade or Longer
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.